<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02620254</url>
  </required_header>
  <id_info>
    <org_study_id>Mastocytosis Registry</org_study_id>
    <nct_id>NCT02620254</nct_id>
  </id_info>
  <brief_title>Mast Cell Connect: A Registry for Patients With Mastocytosis</brief_title>
  <official_title>Mast Cell Connect: A Registry for Patients With Mastocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Blueprint Medicines Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>PatientCrossroads</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Blueprint Medicines Corporation</source>
  <brief_summary>
    <textblock>
      The Mast Cell Connect Registry is a voluntary, observational database that will capture&#xD;
      demographic, socioeconomic, and disease information directly from patients with mastocytosis&#xD;
      via a secure web-based tool. No experimental intervention is involved.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mastocytosis is an extremely rare and heterogeneous spectrum of diseases characterized by the&#xD;
      buildup of genetically altered mast cells. Patients experience a wide range of symptoms and&#xD;
      in some cases, mast cell buildup can lead to organ dysfunction and failure. Current&#xD;
      treatments address disease symptoms and not the underlying cause. To facilitate the&#xD;
      development of new therapies for mastocytosis, it is important for the community to support&#xD;
      clinical trials and to document the impact of the disease, including disease natural history&#xD;
      and the impact on patients, in a systematic way. Mast Cell Connect is a web-based registry&#xD;
      that allows mastocytosis patients and caregivers to enter information about the experience of&#xD;
      the patient living with mastocytosis directly into an online data collection tool.&#xD;
&#xD;
      The Mast Cell Connect Registry allows mastocytosis patients and caregivers to enter&#xD;
      information about the experience of the patient living with mastocytosis directly into a&#xD;
      web-based data collection tool. Two forms of data will be collected: responses to surveys&#xD;
      administered on the web-based portal, and de-identified data curated from medical reports&#xD;
      uploaded by patients or their caregivers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Actual">January 2021</completion_date>
  <primary_completion_date type="Actual">January 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Further the understanding of the epidemiology of mastocytosis and its subtypes</measure>
    <time_frame>Through completion of the study</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Improve the collective understanding of the natural history of mastocytosis and its impact on patients</measure>
    <time_frame>Through completion of the study</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Assist in the development of mastocytosis therapy by increasing participation in clinical trials and other research studies for patients with mastocytosis</measure>
    <time_frame>Through completion of the study</time_frame>
  </other_outcome>
  <enrollment type="Actual">743</enrollment>
  <condition>Mastocytosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with a diagnosis of mastocytosis, including systemic mastocytosis and cutaneous&#xD;
        mastocytosis and any subtypes of these diseases.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Any patient with a diagnosis of mastocytosis, including systemic mastocytosis and&#xD;
             cutaneous mastocytosis and any subtypes of these diseases, who is willing and able to&#xD;
             provide written online informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  None&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony L Boral, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Blueprint Medicines Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Registry participation is worldwide and not limited to this facility</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mastcellconnect.org</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://www.patientcrossroads.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 19, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mastocytosis</keyword>
  <keyword>cutaneous mastocytosis</keyword>
  <keyword>urticaria pigmentosa</keyword>
  <keyword>telangiectasia macularis eruptiva perstans (TMEP)</keyword>
  <keyword>diffuse cutaneous mastocytosis</keyword>
  <keyword>solitary cutaneous mastocytosis</keyword>
  <keyword>systemic mastocytosis</keyword>
  <keyword>indolent systemic mastocytosis</keyword>
  <keyword>smoldering systemic mastocytosis</keyword>
  <keyword>aggressive systemic mastocytosis</keyword>
  <keyword>systemic mastocytosis with associated clonal hematologic non-mast cell lineage disease</keyword>
  <keyword>mast cell leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastocytosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

